by Clinical Neuropsychologist Online | Thursday, October 8, 2026 | Dementia
Abstract BACKGROUND Tau pathology in Alzheimer’s disease (AD) propagates along the brain’s connectome, yet the mechanisms by which tau drives neuronal dysfunction remain unclear. We hypothesized that dysfunction primarily emerges in regions close to...
by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Neurorehabilitation
. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | October 7, 2026 Neuro-Rehab Previous Page
by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia
Abstract INTRODUCTION Anti-amyloid therapies can slow Alzheimer’s disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti-amyloid treatment for...
by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia
Abstract INTRODUCTION Whether glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) activation lowers Alzheimer’s disease (AD) risk via peripheral metabolic improvement or direct neuroprotection remains unclear. METHODS Using blood and brain-cortex cis-acting...
by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia
Abstract INTRODUCTION Biological Alzheimer’s disease (AD) pathology does not fully explain the marked heterogeneity in clinical severity or progression. We investigated whether patient-derived induced microglia-like cell (iMG) profiles capture a functional...
